Analyst Update: Tandem Diabetes Care Inc, Intersect ENT Inc, and Eagle Pharmaceuticals Inc

Analysts are weighing in on Tandem Diabetes Care Inc (TNDM), Intersect ENT Inc (XENT), and Eagle Pharmaceuticals Inc (EGRX)

Nov 2, 2016 at 3:25 PM
facebook X logo linkedin


Analysts are weighing in on medical device makers Tandem Diabetes Care Inc (NASDAQ:TNDM) and Intersect ENT Inc (NASDAQ:XENT), as well as biotech stock Eagle Pharmaceuticals Inc (NASDAQ:EGRX). Here's a quick roundup of today's brokerage notes on TNDM, XENT, and EGRX.

  • TNDM is plummeting today, down 57.9% at $2.25 -- after touching a record low of $1.95 earlier -- following the company's first revenue miss in two years. The brokerage crowd was quick to jump on TNDM -- which is second to only drugmaker Cempra Inc (NASDAQ:CEMP) on the list of worst-performing Nasdaq stocks -- with Stifel cutting TNDM to "hold" from "buy," and absolutely obliterating its price target, to $3.50 from $15, citing concerns about decreased revenue as consumers put off purchases ahead of Medtronic PLC's (NYSE:MDT) new insulin pump release in spring of 2017. Meanwhile, Wedbush chopped TNDM's price target to $11 from $20, and Deutsche Bank slashed its target to $9 from $14. Tandem Diabetes Care Inc shares are now down 80% since the beginning of 2016, and the stock landed on the short-sale restricted (SSR) list today. With 9.7% of TNDM's float sold short, it would take nearly three-and-a-half weeks of trading to buy back these bearish bets, at TNDM's average daily volume.
  • XENT is also taking it on the chin today -- and on the SSR list -- behind just CEMP and TNDM on the list of worst Nasdaq stocks, with the shares trading 42.7% lower at $8.43, and just off a record low of $7.65. XENT is due to report earnings this evening, but the stock is plunging after an unfavorable rule change from the Centers for Medicare & Medicaid Services (CMS). J.P. Morgan Securities downgraded XENT to "neutral" from "overweight," and cut its price target to $16 from $25, citing potential revenue headwinds to XENT's sinus surgery implant, Propel, stemming from the new CMS reimbursement rules. Likewise, Canaccord Genuity noted "heightened concerns about 2017 growth projections given yesterday's CMS final rule," but maintained a "buy" rating. Intersect ENT Inc (NASDAQ:XENT) sports a Schaeffer's put/call open interest ratio (SOIR) of a whopping 25.86, which sits in the 97th percentile of its annual range, suggesting short-term option players have rarely been more put-skewed over the last 12 months.

  • On the other side of the spectrum, EGRX is among the top Nasdaq performers today, trading up 20.9% at $69.18, after the CMS established a specific billing code for its BENDEKA blood cancer injection. Boosting the shares even further is some optimistic analyst attention from William Blair, which raised its target price to $97 from $83. The biotech has spent most of 2016 attempting to recover from a March bear gap, and has more than doubled from its mid-April lows. In the option pits, Eagle Pharmaceuticals Inc (NASDAQ:EGRX) bulls are likely cheering today's news, given the stock's 50-day call/put volume ratio of 11.36 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which sits higher than 93% of all other readings from the past year.
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI